Shanghai Haohai Biological Technology Co., Ltd. (“Haohai Biotech”) released its monthly return for the period ended 30 April 2026, confirming a stable capital structure and ongoing share-buyback housekeeping.

Authorised/Registered Capital • Total registered share capital remained unchanged at RMB 229.98 million, comprising 35.93 million H shares and 194.05 million A shares, each with a par value of RMB 1.00.

Issued Shares and Public Float • H shares: 35.93 million in issue with no treasury stock. The company affirmed compliance with the Hong Kong Exchange’s minimum 5 % public-float requirement for PRC issuers. • A shares: 190.20 million outstanding and 3.85 million held in treasury; no monthly movement recorded.

Share Repurchase Status • A total of 0.69 million H shares repurchased on 10 June 2025 remain pending cancellation. No new repurchases, cancellations, or other share movements occurred during April 2026.

Capital-Raising Instruments • The company reported no outstanding or newly issued share options, warrants, convertibles, or other equity-linked instruments.

Regulatory Compliance • The filing reconfirmed that all share transactions complied with applicable listing rules, legal requirements, and corporate approvals.